Scancell Share Discussion Threads

[mikethebike4] 26/1/2018 08:44

looking at the share price and given the current circumstances looks like a fund raising coming up
- but maybe wrong, usually (but not always) am

[gazza] 26/1/2018 07:32

Yes, thanks goosed.There's no point being able to predict who will respond to treatment if said treatment is not widely and readily available.There are many parties with a vested interest in the success of Scanless, not least of which those unfortunate enough to contract this awful disease.

[bermudashorts] 25/1/2018 18:54

Interesting Gooosed, thanks for sharing.

[gooosed] 25/1/2018 18:26

While it's quiet - this Abstract may be of interest to some :

"Immuno-Oncology Summit August 28 - September 01, 2017, Boston, MA

Assessment of Autoantibodies for Prediction of Disease Recurrence in
Subjects Undergoing SCIB1 Vaccination for Malignant Melanoma

Jared Allen
Jared Allen[1,3]; Isabel Macdonald[1]; Graham Healey[1]; Ian Daniels[2]; Lindy Durrant[2]; Andrea Murray[1]

Oncimmune Ltd., Clinical Sciences Building, Hucknall Road, Nottingham, NG5 1PB UK
[1] Oncimmune Ltd., Clinical Sciences Building, Hucknall Road, Nottingham, NG5 1PB

UK; [2] Scancell Ltd., City Hospital, Department of Clinical Oncology, Hucknall Road, Nottingham, NG5 1PB UK;

[3] University of
Nottingham, University Park, Nottingham, NG7 2RD UK

Introduction: The cancer vaccine, SCIB1, is currently undergoing phase I/II clinical trials for the treatment of melanoma. SCIB1 is a plasmid DNA, encoding a human IgG1 molecule engineered to express two CD8 and two CD4 T-cell epitopes derived from the melanoma antigens Tyrosinase-Related Protein 2 (TRP2) and gp100. Immunisation with SCIB1 results in expression of the engineered antibody, leading to an immune response against tumour cells expressing the TRP2 and gp100 antigens.

Measurement of autoantibodies is already being used for the early detection of cancer. As SCIB1 inhibits cancer through activation of an immune response, we hypothesise that assessment of the associated autoantibodies to TRP2 and gp100, along with other tumour associated autoantigens, may provide useful prognostic information.

Methods: Sixteen patients with fully resected Stage III or Stage IV melanoma received five doses of the SCIB1 vaccine over a 6 month period, with blood samples taken immediately prior to vaccination on days 0, 21, 42, 84, and 168, with additional samples taken on days 49, 91, and 175. All samples were assessed by indirect ELISA to measure levels of autoantibody binding to a panel of 45 tumour associated autoantigens, each measured in singlet against two concentrations of antigen.

Results: Autoantibody measurements at each collection time-point were explored via
unsupervised cluster analysis to determine whether humoral immune response was predictive of vaccine response. Analysis of the resulting cluster groups revealed that similarity clustering of samples was present in pre-treatment time point 0 samples, and that one group was predictive of disease recurrence with 80% sensitivity and 82% specificity. The groups defined by the cluster analysis were then used to create a predictive regression model for cluster group. The predictive score returned by the trained model utilized autoantibody binding data from seven of the tumour associated autoantigens, and correctly classified the cluster grouping of all sixteen pre-treatment samples. This predictive regression model was subsequently applied to the pre-treatment time point 0 samples of an additional blinded cohort of four patients with resected tumour. The model was able to correctly predict that none of these samples would undergo disease recurrence during the course of the study.

Conclusions: We have developed a methodology for predicting melanoma recurrence in
patients treated with SCIB1 using a panel of 7 tumour associated autoantibodies.
Whilst phase I/II trial outcomes for SCIB1 are highly encouraging, identifying a cohort of patients prior to SCIB1 treatment who are more likely to show recurrence may aid in patient treatment stratification allowing enhanced surveillance and early intervention. This approach may assist in further improving disease outcome in this cohort of patients."

Has a reassuring ring to it "highly encouraging" - now where's that funding ?

[oldnotwise] 25/1/2018 14:36

Fragma,
I'm not sure you've quoted me correctly!
ATB

[fragma] 25/1/2018 14:19

ONW, What an odd post.

"relentless share price predictions "

serioulsy.

The only relentless share price predictions are made by the relentlessly negative posters.

you hardly see any share price ramping going on in this share.

You're invested in VAL, why no such comments on the complete and utter unfounded uber ramps going on over there ?

[10acious] 25/1/2018 11:33

Nice post.It's good to sit back and think about it!

[tosh 123] 25/1/2018 10:29

ONW
Very succinctly put sir.
I applaud you.

[the real lozan] 25/1/2018 09:42

Rhatton / O N W -
Firstly...*WE ALL* must compliment Rhatton for being recognised as having "an agenda" by ELSIE - The shepherd boy who cries GOAT - for pointing out that half-term results are due soon. - Well done.
.
O N W -
"I remain a "glass half full" person when it comes to Scancell, but as Balerno says we NEED some short term Hard News to assist the SP's voyage out of the doldrums!"
Some might opine that 'The S P is merely SKIRTING the doldrums' at the moment.
No "Hard News" or 'NEWS' of FUNDING at 'injurous terms' to existing shareholders... MIGHT be seen to send the S P { for however short-terms} REALLY into "the doldrums".
.
Just a thought

[agema] 24/1/2018 12:28

Lozan
The knife is stuck in the feet. Just a question of if it will chop off the toes now.Lol.

[rhatton] 24/1/2018 08:46

Terror, how does funding arrive without the share price going to 5p?

[terror] 24/1/2018 07:50

Desperate posting happening on the MFF. Dredging up old news that had no positive impact on the share price what do they believe will happen now?

A miracle is required to stop the share price going to 5p.

That miracle is a business strategy, fully funded with a clear and concise plan for revenue generation.

[tosh 123] 24/1/2018 06:59

Ineptico... Once again , absolute rubbish.
You have no idea what you're talking about.

[drdobson1] 23/1/2018 21:41

Tosh.A very well argued reasonable assessment of why IMM has enjoyed a very clear rise compared to the situation here.
My understanding is also that a lot of IMM shares are institutionally held including the BOD for the long term rather than being flipped as per the SCLP last placeees and the BOD who mainly have options apart from Chiplins buy at 10p.
Contrast your post with the BOFFOON who does the one line put downs which only he understands.
He is dangerous and good job the ASTUTE On here are the voice of reason as compared to the folk on the other place

[tosh123] 23/1/2018 21:30

And with that one post you merely reiterate your complete and utter lack of any understanding what so ever.... You Buffoon !
Firstly Phase III trials, have not only been financed, but they have been completed... Sentiment ? I think not, its down to the FACT that IMM have done exactly what they promised they would do, and completed Phase III.
Secondly, as well as completing Phase III trials ( which could not have had any major side effects otherwise the trial would have been stopped ), They have also announced that the recipients of the drug, and indeed the trial coordinators, have asked to EXTEND the treatment for another 6 months.... Sentiment ? I think not, its down to the fact that the trial has apparently been a success.
The fact that over the last few years, IMM has gradually mitigated risk is exactly why the share price has risen nearly 400%, not sentiment.... Sentiment is driven by risk, the more comfortable people are that their risks are being reduced, the more the share price increases, the two are directly proportional.


rHatton... Unfortunately i think you're right. I would venture that any funding will now be south of the current SP, which is clearly a real kick in the teeth for existing shareholders, especially those who continue to try and support the current levels, by buying more.
There is now a real risk that shareholders will be diluted out of existence.
Clearly, what we all hope for is someone with deep pockets and credibility to ride over the hillside and provide full financial support, for the next 3 years, however, bearing in mind that the " data room " has been seen by numerous candidates for funding, i think this scenario is becoming more and more unlikely.

As i have said before, i will continue to hold " just in case " as if this does make it through the next few years, the potential remains meteoric, but lets not kid ourselves, this is now a longer term investment than it was perceived to be many years ago. I agree that the IP has somewhat increased with the evolution of Modi, but that has not, nor will it, be reflected in the share price until the OBVIOUS RISKS have been mitigated.
All the while we have idiots ramping £6 / share, and claiming zero risk etc, he will be the laughing stock of the BB.

[rhatton] 23/1/2018 20:40

Tosh, completely agree. Funding changes everything here if and when it arrives. The question is can thy do it at this level. I’d guess not!

[inanaco] 23/1/2018 19:18

Imm results are not out yet, ? that's still a £200m Mcap technically nothing has changed.

Must be sentiment ..

[tosh 123] 23/1/2018 17:49

Agema,
exactly what a few of us have been advocating for quite a while now.
The longer there is no news, the longer and deeper the share price will become even further distressed.... that's a FACT.

Unlike a certain cretin, the rest of the humanoid market appreciates that there is still a massive risk element attached to this share.
All this £6 / share nonsense should be banished. Contrary to the idiots many predictions over the last 6 years or so, the risk is there for everyone to see.... the guy has been 100% wrong, 100% of the time.
Remove that risk ( or a large proportion of it ) with concrete news on funding, and then watch it rocket.
Look at IMM, even now, at the end of Phase III trials, the share price still doesn't match the perceived true value, however, what the company has done, is to gradually raise cash and remove certain risk elements, hence the 300% - 400% rise over the last 12 months or so.
If / when the final results are announced ( within 3 months ), then, and only then will the true " potential " be realised via the SP, anyone that thinks potential is ALL valued prior to it being proven, is a BUFFOON.